Health ❯ Healthcare ❯ Oncology

Immunotherapy

Durvalumab Pembrolizumab Melanoma Immunotherapy CAR T-cell Therapy Malignant Melanoma Clinical Trials Adoptive Cell Therapy Combination Therapy PD-1/VEGF Bispecific Antibodies PD-(L)1 Inhibition Patient Care Cemiplimab Recurrent Cancer Subcutaneous Treatment Adjuvant Therapy Domvanalimab and Zimberelimab Sacituzumab Govitecan and Pembrolizumab

FDA Approves Belzutifan With Pembrolizumab as Adjuvant Therapy for Clear Cell Kidney Cancer

Regulators cited LITESPARK-022 results showing reduced recurrence risk, with specific dosing and safety guidance issued.

EMERALD-3 Trial Shows Progression-Free Survival Win for STRIDE Plus Lenvatinib With TACE

Ivonescimab Extends Survival in China Phase 3 Trial for Squamous Lung Cancer

Swedish Study Ties Lower Ipilimumab Dose to Longer Survival and Less Toxicity in Advanced Melanoma